Business reorganisation requires recognition of successor's modified return; draft orders against dissolved transferor quashed and fresh review direct...
Pre-commencement R&D deduction denied where business had not commenced; deeming benefit requires tangible start of manufacture or commercial exploitat...
When a product falls within both a general tariff entry and a specific entry, the specific entry prevails; Active Pharmaceutical Ingredients (APIs) and bulk drugs satisfy the statutory definition of "drug" and are classifiable under the specific entry SI. No. 226 for tariff rate purposes rather than under general chemical headings. The statutory definition of drug is wide and expressly includes substances intended as components of drugs, and regulatory treatment and definitions across drug control rules confirm that APIs retain their character as drugs even when imported for testing, bioequivalence, bioavailability or clinical trials. Consequently, APIs/bulk drugs attract IGST as per SI. No. 226 except where a nil-rated entry applies.
When a product falls within both a general tariff entry and a specific entry, the specific entry prevails; Active Pharmaceutical Ingredients (APIs) and bulk drugs satisfy the statutory definition of "drug" and are classifiable under the specific entry SI. No. 226 for tariff rate purposes rather than under general chemical headings. The statutory definition of drug is wide and expressly includes substances intended as components of drugs, and regulatory treatment and definitions across drug control rules confirm that APIs retain their character as drugs even when imported for testing, bioequivalence, bioavailability or clinical trials. Consequently, APIs/bulk drugs attract IGST as per SI. No. 226 except where a nil-rated entry applies.
Note: It is a system-generated summary and is for quick reference only.
TaxTMI 
of 4805
Join Channel
TaxTMI 
